PMID: 25726029Mar 3, 2015Paper

Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis

Journal of Managed Care & Specialty Pharmacy
Steven R FeldmanMary Helen Tran

Abstract

Dose escalations of biologic agents may be attempted in the management of moderate-to-severe psoriasis. This has implications for the real-world cost of treatment. To examine the utilization patterns and costs associated with the use of etanercept, adalimumab, and ustekinumab among patients with moderate-to-severe psoriasis. This was a retrospective cross-sectional study. Patients with 2 or more medical claims with a diagnosis of psoriasis (excluding psoriatic arthritis) who were enrolled in large employer-sponsored health plans (including a pharmacy benefit) in the United States from January 2007 to March 2012 were identified and extracted from the MarketScan Commercial Encounters Database. Patients aged at least 18 years were required to have 2 or more pharmacy claims for etanercept, adalimumab, or ustekinumab; the index date was the first biologic fill date. Demographics and comorbidities were identified during the 1-year pre-index period, and medication utilization and costs were evaluated in the 1-year post-index period after a titration period according to the product prescribing information (2 weeks to 12 weeks). Medication utilization parameters such as dose escalation, dose reduction, persistence, switching, discontinu...Continue Reading

Citations

Oct 22, 2015·Expert Review of Pharmacoeconomics & Outcomes Research·Nicole C RouseSteven R Feldman
Feb 2, 2017·Journal of the European Academy of Dermatology and Venereology : JEADV·M EspositoG Girolomoni
Apr 28, 2017·Journal of Managed Care & Specialty Pharmacy·Steven R FeldmanYunfeng Li
Oct 10, 2018·Dermatology : International Journal for Clinical and Investigative Dermatology·Antonio CostanzoCarlotta Galeone
Mar 31, 2016·Clinical Reviews in Allergy & Immunology·Yaxiong DengQianjin Lu
May 6, 2017·Clinical Rheumatology·Sergio SchwartzmanJacqueline B Palmer
Nov 22, 2017·Journal of Cutaneous Medicine and Surgery·Robert BissonnetteMarni C Wiseman
May 14, 2019·Current Medical Research and Opinion·Sara HigaAasthaa Bansal
Jan 13, 2018·Expert Review of Clinical Immunology·Lauren SealeSteven R Feldman
Aug 10, 2017·Journal of Cutaneous Medicine and Surgery·Jaclyn A SmithSteven R Feldman
Nov 8, 2019·The Journal of Dermatological Treatment·Mwangi J MurageAbrar Qureshi
Apr 3, 2020·The Journal of Dermatological Treatment·Jashin J WuApril Armstrong
Jul 1, 2020·The Journal of Dermatological Treatment·Xiaoying JiaApril W Armstrong
Apr 14, 2016·Journal of the European Academy of Dermatology and Venereology : JEADV·J C PrinzG Girolomoni
Aug 27, 2015·Journal of Managed Care & Specialty Pharmacy·Lung-I ChengBradley S Stolshek
Feb 28, 2018·Expert Opinion on Biological Therapy·Matteo MegnaNicola Balato
Oct 28, 2017·The Journal of Dermatological Treatment·Daniel J NoJashin J Wu
Dec 28, 2018·Expert Opinion on Pharmacotherapy·Michael S HeathSteven R Feldman
Mar 27, 2020·Patient Preference and Adherence·Andrew BlauveltMwangi J Murage
Mar 28, 2018·Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Società Italiana Di Dermatologia E Sifilografia·Ilaria MarcianòGianluca Trifirò
Mar 6, 2021·Indian Journal of Dermatology, Venereology and Leprology·Shekhar NeemaArun Kumar Yadav
Jan 22, 2020·Dermatology : International Journal for Clinical and Investigative Dermatology·Kristina Callis DuffinMark Lebwohl

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.